Stockreport

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenoca...

Verastem, Inc.  (VSTM) 
Last verastem, inc. earnings: 10/29 04:17 pm Check Earnings Report
US:NASDAQ Investor Relations: verastem.com
PDF At month four, the OS rate was 92.2%; median OS has not been reached 1.5% of patients experienced a reduction in tumors and a disease control rate of 96.7%; nearly ha [Read more]